Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Arbutus Advances Imdusiran; FDA Aligns On Phase 2b Trial Design

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

Arbutus Biopharma has advanced its drug candidate Imdusiran with the FDA's alignment on the Phase 2b trial design, marking a critical regulatory step forward in its clinical development.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a regulatory green light in the US biotech sector for Phase 2b trials on a new RNAi therapeutic. This opens potential partnership and funding channels this quarter if you operate in rare disease or RNA therapies.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

Biotecharbutusimdusiranfdaclinical-trialbiotech